Keywords: |
unclassified drug; clinical trial; fatigue; review; doxorubicin; fluorouracil; interferon; advanced cancer; drug efficacy; drug safety; drug withdrawal; hepatitis c; nonhuman; solid tumor; paclitaxel; cytarabine; neoplasm; animals; carboplatin; multiple cycle treatment; etoposide; thrombocytopenia; lung cancer; cyclophosphamide; dyspnea; sarcoma; thorax pain; pyrazoles; carrier proteins; recombinant proteins; mitoxantrone; daunorubicin; acute myeloblastic leukemia; peripheral edema; headache; hematopoietic stem cell; idarubicin; drug dose increase; epistaxis; heart atrium fibrillation; megakaryocyte; female genital tract tumor; hemorrhoid; megakaryocytes; hydrazines; thrombopoietin; akr 501; eltrombopag; neutralizing antibody; myositis; thrombopoiesis; bloody diarrhea; thrombocytopoiesis; gingiva bleeding; akr-501; amg-531; interleukin-11; dimethoate; interleukin 11; lgd 4665; nip 004; recombinant megakaryocyte growth and development factor; recombinant thrombopoietin; remiplistim; sb 559448; conjunctival hemorrhage; contusion; menorrhagia; thrombocytopenic purpura; benzoic acids; purpura, thrombocytopenic, idiopathic; receptors, fc
|